In France, routine adolescent coverage with the HPV vaccine remains below national goals. The investigators designed the PrevHPV randomized controlled trial to address that gap. The trial evaluated three distinct intervention components delivered to middle-school populations: educational and motivational activities (EMM); school-based vaccination campaigns (FA); and training for General Practitioners (GPs). The study compared these components, alone or in combination, to measure change in vaccine uptake and vaccination intentions among the adolescent cohort.
The study team framed the work as an applied, pragmatic evaluation in school settings. The available abstract identifies the three intervention targets but the provided excerpt does not contain granular operational details — for example, the source did not report the randomization ratio, the number of participating schools, nor the precise content or duration of the EMM sessions. The text likewise omits the schedule and modality of the FA vaccination campaigns and the curriculum or delivery mode used for GP training. Readers will need the full text for implementation fidelity measures and intervention manuals.
The publication posed a mediation analysis question: which changes in adolescents’ knowledge, attitudes, and practices (KAP) after the school-based intervention were linked to higher HPVV uptake and stronger vaccination intentions. Mediation analysis implies that the authors attempted to separate direct effects of the interventions from indirect effects transmitted through changes in KAP domains. The excerpt confirms the analytic focus but does not provide the KAP instrument items, timing of assessments, or statistical approach used in mediation modelling.
The source did not report the primary or secondary endpoints in the provided text beyond referencing uptake and intentions. There is no information here about how uptake was ascertained (self-report, vaccination registry, school records), nor about how intent was measured (single-item question, scaled instrument). Without those details in the excerpt, it is not possible to evaluate potential measurement bias, temporal ordering between mediator and outcome, or whether sensitivity analyses for mediation assumptions were performed.
The trial was reported by Amanda Munoz and colleagues on behalf of the PrevHPV Consortium. The author list includes investigators from multiple French academic and public health institutions, among them the Institut Pasteur, Université Paris Cité, Univ Lyon, Santé publique France, and several university teams across France. The article appears in the journal Vaccine (2026), with DOI 10.1016/j.vaccine.2026.129150 and PubMed identifier 42753385. The supplied excerpt includes institutional affiliations but stops before presenting study results.
The snippet of the PubMed record provided here does not contain quantitative outcomes. The source excerpt did not report vaccination uptake percentages, adjusted effect estimates, confidence intervals, nor mediation pathway coefficients. The text likewise omitted sample size, baseline KAP levels, follow-up duration, and any adverse event or acceptability data. Because those elements are not present in the supplied content, this summary does not infer or extrapolate results; such inferences would require access to the full published article or supplemental materials.
The main limitation of this summary is the incompleteness of the supplied source excerpt. The following key questions remain unanswered in the provided text and require the full article to address:
Investigators and clinicians seeking to interpret the PrevHPV mediation analysis should consult the full Vaccine article for the complete methods, numerical results, and any subgroup or sensitivity analyses. The provided PubMed abstract and bibliographic record confirm the trial question, the three intervention arms (EMM, FA, GP training), authorship, and publication outlet, but do not supply the trial outcomes or mediation findings necessary for evidence appraisal.